Back to top
more

Thermo Fisher Scientific (TMO)

(Real Time Quote from BATS)

$613.00 USD

613.00
175,117

-11.21 (-1.80%)

Updated Sep 11, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Here's Why You Should Hold on to Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.

Here's Why You Should Retain Phibro (PAHC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

by Zacks Equity Research

Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.

Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout

by Zacks Equity Research

Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.

Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher

by Zacks Equity Research

Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher.

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.

Sweta Killa headshot

5 Unbeatable Dividend Growth Stocks for 2022

by Sweta Killa

Beat the market with dividend stocks like Toll Brothers (TOL), Microsoft (MSFT), Avery Dennison (AVY), J.B. Hunt (JBHT) and Thermo Fisher (TMO) in 2022.

The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.

by Zacks Equity Research

Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.

Here's Why You Should Add Omnicell (OMCL) Stock for Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

Riya Anand headshot

3 Diagnostics Stocks in Focus Amid the Omicron Outbreak

by Riya Anand

Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.

Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Thermo Fisher Scientific (TMO) closed the most recent trading day at $667.24, moving +0.27% from the previous trading session.

3 Reasons to Add McKesson (MCK) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.

Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.

    Should Invesco Dynamic Large Cap Growth ETF (PWB) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for PWB

    Quidel's (QDEL) Antigen Tests Successful in Omicron Detection

    by Zacks Equity Research

    The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.

    Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Thermo Fisher Scientific (TMO) closed at $662.73, marking a +1.12% move from the previous day.

    Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

    by Zacks Equity Research

    Sector ETF report for IYH

    Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

    by Zacks Equity Research

    Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

    Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System

    by Zacks Equity Research

    Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.

    PacBio's (PACB) New Surveillance Kit Successful Against Omicron

    by Zacks Equity Research

    PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

    Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide

    by Zacks Equity Research

    Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

    Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

    by Zacks Equity Research

    DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.